Compare ADMA Biologics Inc (ADMA) vs Noble Corporation plc (NE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Noble Corporation plc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Noble Corporation plc trades at $39.3 (market cap $6.12B). The key difference: Noble Corporation plc is far larger — about 2.9× ADMA Biologics Inc's market cap, and Noble Corporation plc pays a 5.21% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NE | |
|---|---|---|
Market Cap | $2.13B | $6.12B |
Sector | Health | Technology |
52-Week High | $20.38 | $54.37 |
52-Week Low | $7.60 | $25.70 |
Enterprise Value | $2.20B | $7.37B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Noble Corporation (NE) trades at $37.41, down 1.53% today, with technical indicators showing a bearish trend despite oversold RSI readings. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing in previous quarters. Fundamentals show steady revenue around $3.3 billion with improving net margins to 7.17% in 2026. Noble recently secured a new three-well drilling contract with BP and completed a $800 million senior notes offering to strengthen its financial position.
The stock presents a compelling valuation case with analyst consensus target of $53.33 representing 43% upside potential. However, recent earnings misses and bearish technical signals suggest near-term volatility. The offshore drilling specialist benefits from contract wins and conservative balance sheet management, though execution risks and oil price sensitivity remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
